Cipla News and Updates

Name: Latest research reports of Cipla Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Cipla Ltd.
Rating: 3
Author: Geojit BNP Paribas

Keep track of all breaking news on Cipla from all sources in a single place.

Cipla Ltd.

16 Jan 2026

1397.50

-2.58%

Lanreotide supply disruption raises concerns over Cipla's earnings

Business Standard

Cipla said supplies of its key US drug Lanreotide will remain constrained after its manufacturing partner paused production following USFDA observations

Number of FII/FPI investors decreased from 1124 to 1085 in Sep 2025 qtr

Cipla Ltd.

16 Jan 2026

1397.50

-2.58%

Cipla slips 5%, hits nine-month low; why pharma stock under pressure?

Business Standard

In the past seven trading days, the stock price of Cipla has slipped 11 per cent from 1,530.25 hit on January 1, 2026.

Cipla Ltd. has an average target of 1697.44 from 9 brokers.

Cipla Ltd.

08 Jan 2026

1397.50

-2.58%

Cipla among 5 F&O stocks with a sharp rise in futures open interest

Economic Times

On January 7, futures open interest rose notably across five F&O stocks, contributing to a cumulative increase of over 10% compared with the previous session. A rise in futures open interest points to a build-up of active contracts, suggesting fresh positioning or expansion of existing positions by traders.

Cipla Ltd. is trading below all available SMAs

Cipla Ltd.

07 Jan 2026

1397.50

-2.58%

Cipla Shares Fall 4% After USFDA Flags Compliance Issues At Pharmathen's Rodopi Facility

NDTV Profit

The form includes nine observations highlighting serious concerns over current Good Manufacturing Practices (cGMP).

Cipla Ltd. is trading below all available SMAs

Cipla Ltd.

23 Dec 2025

1397.50

-2.58%

CIPLA LTD

Hold: Cipla Ltd.

Recommendation Target

Geojit BNP Paribas

Cipla Ltd delivered a steady Q2FY26 performance, supported by strong branded generics in India and continued leadership in its US respiratory business (albuterol MDI). The company's strategic focus on high-growth therapies such as obesity and diabetes (exclusive launch of Tirzepatide Yurpeak in India) underpins its long-term growth potential. However, near-term challenges remain, including the anticipated revenue erosion from the Revlimid cliff, increased R&D intensity weighing on margins, and execution risk related to timely approvals, which could limit earnings visibility and margin recovery in the medium term, thereby warranting a more...

Cipla Ltd. is trading below all available SMAs

Cipla Ltd.

22 Dec 2025

1397.50

-2.58%

Cipla launches inhaled insulin', a needle-free alternative for people with diabetes

Business Line

Cipla Ltd. is trading at high day volume of 4.3M.

Cipla Launches Inhalable Insulin For Diabetes Care

NDTV Profit | 22 Dec 2025 1 more

Cipla Ltd.

19 Dec 2025

1397.50

-2.58%

Cipla to exclusively market and distribute five Pfizer brands in India

Business Standard

Cipla will exclusively market five Pfizer brands in India, adding 400-430 crore of established acute therapies to its portfolio without manufacturing risk

Cipla Ltd. has an average target of 1697.44 from 9 brokers.

Cipla ties up with Pfizer for exclusive marketing of four brands

livemint | 19 Dec 2025

Cipla Ltd.

10 Dec 2025

1397.50

-2.58%

Cipla Launches Drug For Obesity, Diabetes

NDTV Profit

Cipla has launched Yurpeak (tirzepatide), a one-weekly injectable therapy for obesity and type-2 diabetes mellitus.

Cipla Ltd. has an average target of 1697.44 from 9 brokers.

Cipla Ltd.

03 Dec 2025

1397.50

-2.58%

Cipla, Stempeutics launch stem cell therapy for knee osteoarthritis

Business Standard

Approved by the Drug Controller General of India (DCGI), the treatment offers to slow disease progression and promote cartilage maintenance for patients with Grade II and III knee OA